Skip to main content
. 2022 Apr 15;2:100018. doi: 10.1016/j.obpill.2022.100018

Fig. 4.

Fig. 4

Development of anti-obesity medications is following the path of drug development of other metabolic diseases. Like the history of other metabolic diseases, a bias exists among many clinicians that limits pharmacotherapy to treat obesity [[201], [202], [203], [204]].